Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-Combination Bimatoprost and Brimonidine in Glaucoma or Ocular Hypertension
NCT01863953Phase 2Completed
- Sponsor
- Allergan
- Start
- Jun 2013
- Primary completion
- Dec 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimatoprost and brimonidine tartrate + sodium hyaluronate in Glaucoma and ocular hypertension (3 arms), sponsored by Allergan. Primary endpoint: Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP) at Day 42. Started Jun 2013; status: completed.
02
Drugs
bimatoprostbrimonidine tartrate + sodium hyaluronate
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT01863953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863953.